Verona Pharma plc - ADR

Name: Verona Pharma plc - ADR Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Verona Pharma plc - ADR

Stock Card

$106.91

$0.00 (0.00%)

As on 07-Oct-2025 09:30EDT

Market cap

$9,085 Mln

Revenue (TTM)

$168 Mln

P/E Ratio

P/B Ratio

Div. Yield

0 %

Verona Pharma - ADR Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 106.91 High: 106.91

52 Week Range

Low: 31.09 High: 106.93

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-0.4 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-20.9
Debt to Equity

0.9
Book Value

$--
EPS

$-0.8
Face value

--
Shares outstanding

84,978,881

10 Years Aggregate

CFO

$-305.72 Mln

EBITDA

$-402.86 Mln

Net Profit

$-360.30 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Verona Pharma - ADR	130.2	0.6	16.8	234.0	117.4	77.5	--
BSE Sensex^*	-9.1	-1.5	2.9	-3.6	5.9	6.0	10.5
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 07-Oct-2025 | *As on 01-Sep-2026 | #As on 26-Oct-2023

Company	2024	2023	2022	2021	2020	2019	2018
Verona Pharma - ADR	132.0	-23.9	288.8	-4.0	21.7	-40.2	-18.7
S&P Small-Cap 600	7.0	13.9	-17.4	25.3	9.6	20.9	-9.7
BSE Sensex	8.1	18.7	4.4	22.0	15.8	14.4	5.9

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Shareholding Pattern

View Details

About Verona Pharma - ADR

Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase... (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pulmonary disease, as well as cystic fibrosis and asthma. Verona Pharma plc was formerly known as Isis Resources plc and changed its name to Verona Pharma plc in September 2006. The company was incorporated in 2005 and is based in London, the United Kingdom. As of October 7, 2025, Verona Pharma plc operates as a subsidiary of Merck Sharp & Dohme LLC. Read more

President, CEO & Executive Director

Dr. David S. Zaccardelli Pharm.D.
President, CEO & Executive Director

Dr. David S. Zaccardelli Pharm.D.
Headquarters

London
Website

https://www.veronapharma.com

FAQs for Verona Pharma - ADR

What is the current share price of Verona Pharma plc - ADR Today?

The share price of Verona Pharma plc - ADR is $106.91 (NASDAQ) as of 07-Oct-2025 09:30 EDT. Verona Pharma plc - ADR has given a return of 117.36% in the last 3 years.

What is the current PB & PE ratio of Verona Pharma plc - ADR?

Since, TTM earnings of Verona Pharma plc - ADR is negative, P/E ratio is not available.
The P/B ratio of Verona Pharma plc - ADR is 33.01 times as on 05-Nov-2025, a 537 premium to its peers’ median range of 5.18 times.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2024	-27.80	18.82
2023	-37.42	6.40
2022	-34.73	8.56
2021	-9.80	2.72
2020	-8.50	2.19

What is the 52 Week High and Low of Verona Pharma plc - ADR?

The 52-week high and low of Verona Pharma plc - ADR are Rs 106.93 and Rs 31.09 as of 02-Sep-2026.

What is the market cap of Verona Pharma plc - ADR?

Verona Pharma plc - ADR has a market capitalisation of $ 9,085 Mln as on 05-Nov-2025. As per SEBI classification, it is a Small Cap company.

Should I invest in Verona Pharma plc - ADR?

Before investing in Verona Pharma plc - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.